Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.11+0.12 (+0.75%)
Close on Nov 17, 2026Market cap $2.98BP/E –Yield –
Legend Biotech profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Legend Biotech's profit margin for the twelve months ending Mar 31, 2025 was -30.0%. For fiscal 2024 it was -28.2%, against -181.8% the year before. The highest annual figure on record is -5.7% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -28.2% | +153.6 |
| FY2023 | Dec 31, 2023 | -181.8% | +199.7 |
| FY2022 | Dec 31, 2022 | -381.5% | +204.9 |
| FY2021 | Dec 31, 2021 | -586.4% | −231.2 |
| FY2020 | Dec 31, 2020 | -355.2% | −185.8 |
| FY2019 | Dec 31, 2019 | -169.4% | −163.7 |
| FY2018 | Dec 31, 2018 | -5.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -51.8% | +11.9 |
| Q4 FY2024 | Dec 31, 2024 | 14.1% | +196.4 |
| Q3 FY2024 | Sep 30, 2024 | -78.2% | −13.4 |
| Q2 FY2024 | Jun 30, 2024 | -9.8% | +261.8 |
| Q1 FY2024 | Mar 31, 2024 | -63.6% | +244.9 |
| Q4 FY2023 | Dec 31, 2023 | -182.3% | +309.4 |
| Q3 FY2023 | Sep 30, 2023 | -64.8% | +245.7 |
| Q2 FY2023 | Jun 30, 2023 | -271.6% | – |
| Q1 FY2023 | Mar 31, 2023 | -308.5% | – |
| Q4 FY2022 | Dec 31, 2022 | -491.7% | – |
| Q3 FY2022 | Sep 30, 2022 | -310.5% | – |
See a number that looks wrong?